351 related articles for article (PubMed ID: 28266127)
1. Mitochondrial PKC-ε deficiency promotes I/R-mediated myocardial injury via GSK3β-dependent mitochondrial permeability transition pore opening.
Wang S; Zhang F; Zhao G; Cheng Y; Wu T; Wu B; Zhang YE
J Cell Mol Med; 2017 Sep; 21(9):2009-2021. PubMed ID: 28266127
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion.
Gomez L; Paillard M; Thibault H; Derumeaux G; Ovize M
Circulation; 2008 May; 117(21):2761-8. PubMed ID: 18490522
[TBL] [Abstract][Full Text] [Related]
3. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore.
Ananthakrishnan R; Kaneko M; Hwang YC; Quadri N; Gomez T; Li Q; Caspersen C; Ramasamy R
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H333-41. PubMed ID: 19060123
[TBL] [Abstract][Full Text] [Related]
4. Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression: role of protein phosphatases.
Ma H; Yu L; Byra EA; Hu N; Kitagawa K; Nakayama KI; Kawamoto T; Ren J
J Mol Cell Cardiol; 2010 Aug; 49(2):322-9. PubMed ID: 20362583
[TBL] [Abstract][Full Text] [Related]
5. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress.
Townsend PA; Davidson SM; Clarke SJ; Khaliulin I; Carroll CJ; Scarabelli TM; Knight RA; Stephanou A; Latchman DS; Halestrap AP
Am J Physiol Heart Circ Physiol; 2007 Aug; 293(2):H928-38. PubMed ID: 17483234
[TBL] [Abstract][Full Text] [Related]
6. Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore.
Xi J; Wang H; Mueller RA; Norfleet EA; Xu Z
Eur J Pharmacol; 2009 Feb; 604(1-3):111-6. PubMed ID: 19135050
[TBL] [Abstract][Full Text] [Related]
7. Local delivery of PKCepsilon-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation.
Korzick DH; Kostyak JC; Hunter JC; Saupe KW
Am J Physiol Heart Circ Physiol; 2007 Oct; 293(4):H2056-63. PubMed ID: 17675573
[TBL] [Abstract][Full Text] [Related]
8. N6-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3 beta.
Park SS; Zhao H; Jang Y; Mueller RA; Xu Z
J Pharmacol Exp Ther; 2006 Jul; 318(1):124-31. PubMed ID: 16611852
[TBL] [Abstract][Full Text] [Related]
9. Anesthetic-induced preconditioning delays opening of mitochondrial permeability transition pore via protein Kinase C-epsilon-mediated pathway.
Pravdic D; Sedlic F; Mio Y; Vladic N; Bienengraeber M; Bosnjak ZJ
Anesthesiology; 2009 Aug; 111(2):267-74. PubMed ID: 19568162
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore.
Obame FN; Plin-Mercier C; Assaly R; Zini R; Dubois-Randé JL; Berdeaux A; Morin D
J Pharmacol Exp Ther; 2008 Jul; 326(1):252-8. PubMed ID: 18434587
[TBL] [Abstract][Full Text] [Related]
11. Effect of pressure overload on cardioprotection of mitochondrial KATP channels and GSK-3beta: interaction with the MPT pore.
Mozaffari MS; Schaffer SW
Am J Hypertens; 2008 May; 21(5):570-5. PubMed ID: 18437149
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection.
Nishihara M; Miura T; Miki T; Tanno M; Yano T; Naitoh K; Ohori K; Hotta H; Terashima Y; Shimamoto K
J Mol Cell Cardiol; 2007 Nov; 43(5):564-70. PubMed ID: 17931653
[TBL] [Abstract][Full Text] [Related]
13. GSK-3beta, a therapeutic target for cardiomyocyte protection.
Miura T; Miki T
Circ J; 2009 Jul; 73(7):1184-92. PubMed ID: 19506320
[TBL] [Abstract][Full Text] [Related]
14. Temperature preconditioning of isolated rat hearts--a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore.
Khaliulin I; Clarke SJ; Lin H; Parker J; Suleiman MS; Halestrap AP
J Physiol; 2007 Jun; 581(Pt 3):1147-61. PubMed ID: 17395631
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation.
Clarke SJ; Khaliulin I; Das M; Parker JE; Heesom KJ; Halestrap AP
Circ Res; 2008 May; 102(9):1082-90. PubMed ID: 18356542
[TBL] [Abstract][Full Text] [Related]
16. Acute PKCdelta inhibition limits ischaemia-reperfusion injury in the aged rat heart: role of GSK-3beta.
Kostyak JC; Hunter JC; Korzick DH
Cardiovasc Res; 2006 May; 70(2):325-34. PubMed ID: 16542646
[TBL] [Abstract][Full Text] [Related]
17. Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta.
Chanoit G; Lee S; Xi J; Zhu M; McIntosh RA; Mueller RA; Norfleet EA; Xu Z
Am J Physiol Heart Circ Physiol; 2008 Sep; 295(3):H1227-H1233. PubMed ID: 18660440
[TBL] [Abstract][Full Text] [Related]
18. Evidence that hydroxysafflor yellow A protects the heart against ischaemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening.
Liu YN; Zhou ZM; Chen P
Clin Exp Pharmacol Physiol; 2008 Feb; 35(2):211-6. PubMed ID: 17941891
[TBL] [Abstract][Full Text] [Related]
19. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: role of GSK-3beta in myocardial protection against ischemia/reperfusion injury.
Miura T; Nishihara M; Miki T
J Pharmacol Sci; 2009 Feb; 109(2):162-7. PubMed ID: 19179805
[TBL] [Abstract][Full Text] [Related]
20. Post-ischaemic activation of kinases in the pre-conditioning-like cardioprotective effect of the platelet-activating factor.
Penna C; Mognetti B; Tullio F; Gattullo D; Mancardi D; Moro F; Pagliaro P; Alloatti G
Acta Physiol (Oxf); 2009 Nov; 197(3):175-85. PubMed ID: 19432589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
